Evidence map›Paper›PMID 41717582›Full record

ReviewFrontiers in cardiovascular medicine2026

Mechanisms of mitral valve development and disease.

Enshi Wang, Bin Zhou

Abstract readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Commentary: Mechanisms of mitral valve development and disease.Frontiers in cardiovascular medicine · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Enshi WangDepartment of Pediatrics, The University of Chicago, Chicago, IL, United States.
Bin ZhouDepartment of Pediatrics, The University of Chicago, Chicago, IL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The mitral valve apparatus comprises the annulus, valve leaflets, chordae tendineae, and papillary muscles, forming an integrated biomechanical unit essential for unidirectional blood flow. The leaflets and chordae are primarily derived from endocardial cells, and damage to these structures results in either mitral stenosis or mitral regurgitation, depending on the underlying pathology. This review compares three major mitral valve diseases, rheumatic mitral stenosis, congenital mitral stenosis, and myxomatous mitral valve prolapse, to highlight their distinct etiologies, molecular mechanisms, and structural endpoints. Rheumatic mitral stenosis is an acquired immune-mediated disease triggered by Group A streptococcal infection, in which molecular mimicry leads to autoantibody formation and chronic inflammation. Immune-cell infiltration and cytokine release drive the progression of leaflet fibrosis, commissural fusion, calcification, and pronounced chordal shortening, ultimately culminating in fixed obstruction. Large-scale genetic studies have not identified strong causal genes, instead revealing associations with immune-related risk loci, while valve-specific epigenetic mechanisms are poorly explored. Congenital mitral stenosis arises from developmental abnormalities of the mitral valve complex during embryogenesis and is classified into four anatomical subtypes. Due to its low incidence, the condition remains the least studied at the molecular and genetic levels. In contrast, myxomatous mitral valve prolapse is a degenerative, polygenic disorder driven by aberrant TGF

Indexed as

congenital mitral stenosisepigeneticgeneticmitral valvemyxomatous mitral valve prolapserheumatic mitral stenosis

Identifiers

PMID41717582
PMCPMC12913423

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.